Other News
3:19 PM Oct 11, 2018
Public funding highlights: 3Q18
12:15 PM Oct 11, 2018
Menu
- Home
+ - Publications
+
- Archives
+
- BCIQ
+
- Conferences
+
- eLearning
+
- Follow Us
Latest News
10:31 PM Oct 15, 2018
Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data
Pharnext S.A. (Euronext:ALPHA) plans to submit regulatory applications to FDA and EMA in 2H19 for PXT3003...
4:48 PM Oct 15, 2018
Management Tracks: Rhythm, Redpin
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company....
4:20 PM Oct 15, 2018
ICER weighing issuing advice on trial design
The Institute for Clinical and Economic Review is evaluating whether to collaborate earlier than it now...
3:10 PM Oct 15, 2018
FDA guides on minimal residual disease endpoint in hematologic cancer trials
FDA Commissioner Scott Gottlieb highlighted minimal residual disease (MRD)'s potential as a surrogate...
2:19 PM Oct 15, 2018
mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's
Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune...
1:49 PM Oct 15, 2018
Krystal gains on early data for topical gene therapy in skin blistering disease
Krystal Biotech Inc. (NASDAQ:KRYS) added $4.32 (28%) to $20 on Monday when it reported interim data from...
12:33 PM Oct 15, 2018
CMS, PhRMA release dueling plans on price disclosures in ads
The Trump administration released a proposed regulation that would mandate disclosure of prices in DTC...
10:34 AM Oct 15, 2018
New CEO Forster eyes capital raise for F-star
Immuno-oncology company F-star Biotechnology Ltd. (Cambridge, U.K.) named Eliot Forster as CEO, replacing...
7:41 AM Oct 15, 2018
SQZ, Roche expand deal to jointly develop cancer cell therapies
SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-...
3:26 PM Oct 12, 2018
Biotech stocks ride tech rally
Biotech indexes ended the week on a positive note but it wasn’t enough to salvage the week.
3:20 PM Oct 12, 2018
FDA panel votes in favor of AcelRx's pain candidate
FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 10-3 that the benefit-risk profile...
3:04 PM Oct 12, 2018
Opdivo misses survival endpoint in Phase III for SCLC
Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab missed the primary endpoint of improving overall...
2:00 PM Oct 12, 2018
Gene editing creates offspring from same-sex parents
Chinese researchers showed it may be possible to create viable offspring from same-sex parents, pushing...
1:53 PM Oct 12, 2018
iPS cell-derived models offer new opportunities for drug screening
New models for Down syndrome and amyotrophic lateral sclerosis harness patient-derived induced pluripotent...
1:47 PM Oct 12, 2018
Iovance raises $219M for Phase II trials
Iovance Biotherapeutics (NASDAQ:IOVA) raised $219.3 million in a follow-on Friday to fund five ongoing...
5:15 AM Oct 12, 2018
Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS
Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis...
3:05 PM Oct 11, 2018
Advisory panel narrowly rejects oliceridine for acute pain
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval...
2:53 PM Oct 11, 2018
Inter Partes Review to be more favorable to biotech
The U.S. Patent and Trademark Office (PTO) finalized a rule requiring higher standards for invalidating...
1:07 PM Oct 11, 2018
Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair
Cancer company VisionGate Inc. (Phoenix, Ariz.) hired John Glasspool as chief operating and strategy...
11:15 AM Oct 11, 2018
FDA lifts hold on IND for CRISPR's sickle cell trial
CRISPR Therapeutics AG (NASDAQ:CRSP) and partner Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said late...
About Biocentury
Contact
Support
Products & Solutions
Legal
- Follow Us
What is BioCentury?
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.